ストックスクリーナーアプリを入手
1.21
3.97%
-0.05
アフターアワーズ：
1.21
Erasca Inc (ERAS) 最新ニュース
Teacher Retirement System of Texas Buys 12,345 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Insiders Lose Out As Stock Sinks To US$1.21 - simplywall.st
Erasca stock hits 52-week low at $1.23 amid market challenges - Investing.com India
Erasca (NASDAQ:ERAS) Coverage Initiated by Analysts at Raymond James - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Swiss National Bank - Defense World
Erasca (NASDAQ:ERAS) Now Covered by Analysts at Raymond James - Defense World
Raymond James sets $5 target for Erasca stock, cites valuation gap By Investing.com - Investing.com South Africa
Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation - Nasdaq
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Raymond James sets $5 target for Erasca stock, cites valuation gap - Investing.com India
Raymond James Initiates Erasca at Outperform With $5 Price Target - MarketScreener
Erasca initiated with an Outperform at Raymond James - TipRanks
Charles Schwab Investment Management Inc. Buys 39,066 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting - The Manila Times
Game-Changing Cancer Treatments: Erasca Reveals 3 Novel Drug Breakthroughs at AACR 2025 - Stock Titan
Bank of New York Mellon Corp Grows Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
What is HC Wainwright’s Estimate for Erasca FY2029 Earnings? - Defense World
The Goldman Sachs Group Has Lowered Expectations for Erasca (NASDAQ:ERAS) Stock Price - Defense World
Erasca (NASDAQ:ERAS) Earns “Buy” Rating from HC Wainwright - Defense World
Erasca, Inc. Reports 2024 Financial and Strategic Progress - TipRanks
Erasca Inc. (ERAS) reports earnings - Quartz
ERASCA Earnings Results: $ERAS Reports Quarterly Earnings - Nasdaq
Erasca, Inc. SEC 10-K Report - TradingView
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results - The Manila Times
Erasca's $440M War Chest Powers Two Groundbreaking Cancer Drugs Into 2025 Trials - StockTitan
Erasca (ERAS) Expected to Announce Earnings on Wednesday - Defense World
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) Price Target at $5.70 - Defense World
Morgan Stanley Reaffirms Overweight Rating for Erasca (NASDAQ:ERAS) - Defense World
Rhumbline Advisers Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge - TipRanks
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by New York State Common Retirement Fund - Defense World
Erasca stock hits 52-week low at $1.32 amid market challenges - Investing.com Australia
Erasca Inc Still Hasn’t Convinced Analysts? - Stocks Register
Erasca stock hits 52-week low at $1.5 amid market challenges - Investing.com Australia
Erasca stock hits 52-week low at $1.5 amid market challenges By Investing.com - Investing.com South Africa
Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Investor’s Toolkit: Key Ratios for Assessing Erasca Inc (ERAS)’s Performance - The Dwinnex
Erasca Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Erasca Inc [ERAS] Records 200-Day SMA of $2.5522 - Knox Daily
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
BlackBerry Ltd [BB] Records 200-Day SMA of $2.77 - Knox Daily
Erasca (NASDAQ:ERAS) Stock Price Down 6.1%What's Next? - MarketBeat
Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex
Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News
Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha
What Are You Thinking About Investing In Erasca Inc (NASDAQ: ERAS) Stock? - Stocks Register
Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):